TEM Stock Risk & Deep Value Analysis
Tempus AI Inc
Healthcare • Health Information Services
DVR Score
out of 10
What You Need to Know About TEM Stock
We analyzed Tempus AI Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TEM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is TEM Stock?
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
High
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for TEM?
- ⚠
Regulatory scrutiny over data privacy or AI model bias (ongoing risk)
- ⚠
Key competitor launches a highly similar or superior data/AI platform
- ⚠
Significant slowdown in pharmaceutical R&D spending affecting partnerships
- ⚠
Adverse outcome in a high-profile clinical trial relying on Tempus insights
Unlock TEM Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Tempus AI Inc (TEM) Do?
Market Cap
$10.94B
Sector
Healthcare
Industry
Health Information Services
Employees
2,400
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaboration agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology, as well as strategic collaboration with Personalis, Inc. and Whitehawk Therapeutics, Inc. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Visit Tempus AI Inc WebsiteIs TEM Stock Undervalued?
Unlock the full AI analysis for TEM
Get the complete DVR score, risk analysis, and more
Does TEM Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is durable due to the unique, ever-growing, real-world multi-modal data assets that are incredibly difficult and costly to replicate. As the platform integrates deeper into clinical and research ecosystems, switching costs for partners increase, and the network effect strengthens the data advantage.
Moat Erosion Risks
- •Competitors developing similar large-scale, high-quality data consortiums or open-source initiatives
- •Regulatory changes restricting data access, sharing, or privacy requirements
- •Rapid advancements in generalized AI diminishing the value of specialized models
TEM Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive TEM Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated late April/early May 2026)
- •Announcement of new major pharmaceutical or academic research partnership
- •Expansion of AI platform features into new disease specific modules
Medium-Term (6-18 months)
- •Further penetration into European or Asian markets
- •Integration of Tempus AI into major hospital networks' standard clinical workflows
- •Key publications demonstrating improved clinical outcomes or drug discovery acceleration using Tempus platform
Long-Term (18+ months)
- •Establishment as the dominant AI operating system for precision oncology and beyond
- •Significant acceleration in drug development timelines and success rates for partner companies
- •Industry-wide adoption of multi-modal data standards pioneered by Tempus
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for TEM?
- ✓
Acceleration in revenue growth and gross margin improvement
- ✓
Announcement of new, high-value strategic partnerships or acquisitions that expand data assets/market reach
- ✓
Evidence of Tempus AI platform impacting specific drug approvals or clinical trial successes
- ✓
Effective management of cash burn while aggressively expanding
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TEM (Tempus AI Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
